In clinic, the full PPARγ agonists TZDs are very effective in glycemic control but have multiple adverse effects such as obesity, water retention, and increased risk of cardiovascular diseases and bone fractions. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.